New York University Langone Medical Center has released results of an Alzheimer’s disease study that shows combining a specific care management program with commonly prescribed drugs multiplies the drug’s ability to improve daily function by roughly 7.5 times and stalls some of the disease’s effects.
"Alzheimer's and dementia clinicians have known for some time that medication alone is not enough to stop disease progression," research principal investigator Dr. Barry Reisberg, director of the Fisher Alzheimer Disease Education and Resources program at NYU Langone, said in a statement. "Our new research shows that a comprehensive, patient-centered care program brings significant benefits in daily activities, which are important to individuals with Alzheimer's and those who care for and about them."
The findings come via a randomized trial developed at NYU Langone Medical Center. Results of the trial were presented in London in July at the Alzheimer’s Association International Conference 2017.
"While there are many great resources for people with Alzheimer's and their families within communities, direct training in basic skills in more severe and more disturbed persons with Alzheimer's is an underutilized and understudied treatment method in the clinic setting that has not been studied," Reisberg said.